# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-12-2025 | 06-30-2025 | 10-Q | |
2 | 05-13-2025 | 03-31-2025 | 10-Q | |
3 | 03-18-2025 | 12-31-2024 | 10-K | |
4 | 11-14-2024 | 09-30-2024 | 10-Q | |
5 | 08-29-2024 | 06-30-2024 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, ...
- SEC Filing
Silexion's SIL204 showed strong anti-tumor effects in preclinical tests, reaching major metastasis sites in pancreatic canc...
Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech ...
SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Tra...
New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tu...